Wellbutrin (bupropion) is neither an SSRI nor an SNRI. It belongs to a different class entirely: norepinephrine-dopamine reuptake inhibitor, or NDRI. That distinction is not just a technicality on a pharmacology exam. Bupropion has no meaningful activity on the serotonin system, which is the defining feature of both SSRIs and SNRIs, and that absence shapes nearly everything about how the drug feels, what side effects it causes, and who it works best for.
What Makes Bupropion an NDRI
SSRIs block the reuptake of serotonin. SNRIs block the reuptake of both serotonin and norepinephrine. Bupropion skips serotonin altogether and instead blocks the reuptake of norepinephrine and dopamine, keeping more of those two chemicals active in the brain. Preclinical and clinical data confirm that bupropion acts through this dual inhibition and is devoid of clinically significant serotonergic effects.1PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor That is why some clinicians call it an “atypical” antidepressant, though the more precise label is NDRI.2PubMed Central. Antidepressant efficacy and side-effect burden: a quick guide for clinicians
The drug is also structurally unusual. Bupropion is a trimethylated monocyclic phenylaminoketone, which in plain English means it looks nothing like the molecules behind most other antidepressants.3Profiles of Drug Substances, Excipients and Related Methodology. Bupropion Hydrochloride Its chemical backbone is actually closer to cathinone, a naturally occurring stimulant found in the khat plant, than to anything in the SSRI or SNRI families.4PubMed Central. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release That structural quirk helps explain why bupropion feels different from serotonin-based antidepressants for many people.
The Role of Metabolites
One detail that gets overlooked in simple NDRI vs. SSRI discussions: much of bupropion’s actual work in the brain appears to be done not by the parent drug itself but by its main metabolite, hydroxybupropion. After you take a pill, your liver converts bupropion into hydroxybupropion, and modeling studies predict that this metabolite is the primary inhibitor of both the dopamine and norepinephrine transporters at typical therapeutic doses.5Drug Metabolism and Disposition. Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations This matters because genetic variation in the liver enzyme responsible for that conversion (CYP2B6) can change how much active metabolite you actually produce, something covered further below.
Why the Serotonin Gap Changes the Side-Effect Picture
The most practical consequence of bupropion being an NDRI rather than an SSRI or SNRI is its side-effect profile. The three side effects people complain about most with serotonin-based antidepressants are sexual dysfunction, weight gain, and sedation. Because bupropion has no serotonergic activity, those problems are far less common with it.1PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Sexual Function
Sexual side effects are one of the biggest reasons people stop taking SSRIs. These can include reduced desire, difficulty with arousal, and trouble reaching orgasm. Bupropion causes significantly less sexual dysfunction than SSRIs, and there is robust evidence backing that distinction.6PubMed. Bupropion and SSRI-induced side effects In fact, bupropion is sometimes added alongside an SSRI or SNRI specifically to counteract the sexual side effects the serotonin-based drug created. Controlled and open-label studies support bupropion’s effectiveness in reversing antidepressant-associated sexual dysfunction when used in combination.7PubMed. Use of bupropion in combination with serotonin reuptake inhibitors
Weight
Weight gain is common with SSRIs and SNRIs. Studies consistently show significant weight increases during monotherapy with those drug classes.8PubMed Central. Effect of comedication of bupropion and other antidepressants on body mass index Bupropion tends to do the opposite. A systematic review of antidepressant effects on weight found that weight loss, not gain, was associated with bupropion treatment.9PubMed. Effects of antidepressant and antipsychotic use on weight gain: A systematic review This has made bupropion particularly popular among patients and prescribers worried about metabolic effects. It is also part of the combination drug naltrexone-bupropion (Contrave), which is FDA-approved specifically for weight management.
What Bupropion Is Approved For
Bupropion has three FDA-approved uses: major depressive disorder (marketed as Wellbutrin), smoking cessation (marketed as Zyban), and prevention of seasonal affective disorder (SAD). The smoking cessation angle is interesting because it takes advantage of an additional pharmacological trick: bupropion weakly blocks nicotinic acetylcholine receptors. That receptor antagonism may reduce the rewarding effects of nicotine, making it easier to stay off cigarettes.10PubMed. How does bupropion work as a smoking cessation aid?
For seasonal depression, the evidence is solid. A Cochrane review covering three large randomized trials with about 1,100 participants found that bupropion XL roughly halved the risk of a depressive episode recurring during the fall-winter season compared with placebo.11PubMed Central. Second-generation antidepressants for preventing seasonal affective disorder in adults Across those three studies, depression recurrence rates in the bupropion groups ranged from about 13 to 19 percent, compared to 21 to 31 percent on placebo.12PubMed. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL
Off-Label Use for ADHD
Because bupropion raises dopamine levels, clinicians have long been interested in it as an alternative to stimulants for attention-deficit/hyperactivity disorder. It is not FDA-approved for this purpose, but off-label prescribing is common.13PubMed Central. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults A multisite randomized controlled trial found that about 53 percent of adults taking bupropion XL met responder criteria for ADHD symptoms, compared to 31 percent on placebo, with a moderate effect size.14PubMed. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study That effect is smaller than what you get with first-line stimulant medications, but bupropion fills a niche for people who cannot tolerate stimulants, have a history of substance use, or are looking for an antidepressant that also helps with focus.
A smaller placebo-controlled trial showed trends favoring bupropion SR for adult ADHD, though results reached significance on only one measure, likely reflecting the study’s limited size.15PubMed Central. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial The overall picture is that bupropion helps with ADHD, but modestly compared to dedicated ADHD medications.
Anhedonia and Emotional Blunting
A frustrating irony of serotonin-based antidepressants is that they can sometimes treat sadness while leaving people feeling emotionally flat. That blunted, “I don’t care about anything” quality is one reason patients report dissatisfaction even when their core depressive symptoms improve. Brain imaging research suggests that bupropion may offer an advantage here. Studies found that bupropion increased brain activity during both reward and aversion processing, which may help explain why catecholaminergic antidepressants could be more effective for anhedonia and emotional blunting compared to SSRIs.16CentAUR. Anhedonia in depression and the case for refining its treatment: insights from examining the neural effects of catecholaminergic antidepressants If your depression manifests less as sadness and more as an inability to feel pleasure or motivation, bupropion’s dopamine activity makes it a logical first consideration.
Anxiety and the Stimulating Flip Side
Bupropion’s activating quality is a double-edged sword. The same dopamine and norepinephrine boost that makes it energizing, weight-neutral, and good for focus can also provoke or worsen anxiety, particularly at higher doses.17Wiley Online Library. Bupropion and Anxiety: A Brief Review If your depression comes with significant anxiety, restlessness, or insomnia, bupropion alone may not be the right fit, and some prescribers will start at a lower dose and increase gradually to see how you respond. SSRIs and SNRIs, for all their other drawbacks, are generally more calming and are first-line treatments for most anxiety disorders. This is probably the most common misconception about bupropion: it is not a universally “better” antidepressant. It is a better antidepressant for a certain symptom profile and a worse one for another.
Combining Bupropion with SSRIs or SNRIs
Because bupropion works on entirely different neurotransmitter systems than serotonin-based drugs, it is frequently combined with an SSRI or SNRI. This combination approach does three things at once: it broadens the neurochemical coverage (serotonin plus dopamine plus norepinephrine), it can boost antidepressant response in patients who did not respond fully to either drug alone, and it can reduce the sexual side effects and weight gain driven by the serotonin drug. Available data suggest this combination is generally well tolerated.7PubMed. Use of bupropion in combination with serotonin reuptake inhibitors
Bipolar Depression and Mood-Switch Risk
Antidepressants can trigger manic or hypomanic episodes in people with bipolar disorder, which is why prescribers are cautious about using them in that population. Among antidepressants, however, the risk is not uniform. A systematic review of naturalistic studies found that tricyclic antidepressants carry the highest likelihood of triggering a mood switch, while bupropion carries the lowest.18PubMed. A systematic review of manic/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs A head-to-head study comparing three antidepressants as add-ons to mood stabilizers in bipolar depression confirmed the pattern: venlafaxine (an SNRI) had the highest relative risk of switching, and bupropion the lowest.19PubMed. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers That lower switching risk, likely connected to its lack of serotonergic activity, has made bupropion one of the antidepressants clinicians feel most comfortable prescribing alongside a mood stabilizer in bipolar depression.
Discontinuation Is Generally Easier
Withdrawal symptoms after stopping an antidepressant are a real problem with many serotonergic drugs. Dizziness, brain zaps, irritability, nausea, and flu-like symptoms can persist for weeks during tapering. A large pharmacovigilance analysis of over 31,000 reports from the WHO’s global database found that the strongest disproportionate reporting of withdrawal syndromes was for paroxetine (an SSRI), duloxetine, venlafaxine, and desvenlafaxine (all SNRIs).20Springer Nature. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database Bupropion was notably absent from the drugs with the strongest withdrawal signals. While stopping any psychotropic medication abruptly is not recommended, bupropion discontinuation tends to be smoother than tapering off an SSRI or SNRI.
Genetic Variation in Drug Processing
Your body converts bupropion to its active metabolite primarily through a liver enzyme called CYP2B6, and people carry different versions of the gene that codes for this enzyme. Individuals with reduced-function genetic variants (such as CYP2B6*6 or *18) produce less hydroxybupropion, meaning the drug’s active form reaches lower blood levels.21PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state Other variants, like CYP2B6*4, may increase conversion.22PubMed Central. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition
These variants are not evenly distributed across populations. CYP2B6*6, for instance, is fairly common worldwide but at varying frequencies depending on ancestry. What this means practically is that two people on the same dose of bupropion can have meaningfully different amounts of active drug in their brains. That could partly explain why some people feel bupropion is life-changing while others barely notice it. Pharmacogenomic testing for CYP2B6 exists, though it is not yet part of standard prescribing for most clinicians.
The Dextromethorphan-Bupropion Combination
One of the more interesting recent developments is Auvelity, a combination of dextromethorphan and bupropion approved in 2022 for major depressive disorder. In this pairing, bupropion plays a dual role. It contributes its own antidepressant activity via dopamine and norepinephrine reuptake inhibition, and it also serves as a metabolic shield: bupropion inhibits CYP2D6, the liver enzyme that normally breaks down dextromethorphan very quickly, allowing dextromethorphan to reach higher and sustained blood levels.23PubMed Central. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder Dextromethorphan, in turn, works through a completely different pathway: it blocks NMDA receptors and activates sigma-1 receptors, modulating the glutamate system.24American Journal of Therapeutics. Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder The result is a drug that hits three neurotransmitter systems at once: dopamine, norepinephrine, and glutamate, while still avoiding serotonin in any major way. Clinical trials showed faster onset of antidepressant effects compared with bupropion alone, which has generated interest for patients who need quicker relief.
Misuse Potential
Because bupropion’s chemical structure resembles cathinone, and because it acts on dopamine (the neurotransmitter most associated with reward), the question of abuse potential comes up. At standard oral doses, the drug’s dopamine effects are too gradual to produce a high. But cases of misuse have been reported since the 1980s, particularly among incarcerated individuals and people with existing substance use disorders, who sometimes crush and snort the tablets to achieve a faster dopamine surge.25PubMed Central. Bupropion abuse and overdose Extended-release formulations help reduce this risk because they are harder to abuse intranasally, but it is worth knowing that bupropion is not completely devoid of misuse potential, even though it is not a controlled substance.